| 1. |
Friedman SL. Evolving challenges in hepatic fibrosis[J]. Nat Rev Gastroenterol Hepatol, 2010, 7(8):425-436.
|
| 2. |
Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity[J]. Cell, 2006, 124(4):783-801.
|
| 3. |
Takeuchi O, Akira S. Pattern recognition receptors and inflammation[J]. Cell, 2010, 140(6):805-820.
|
| 4. |
Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis[J]. Nat Med, 2007, 13(11):1324-1332.
|
| 5. |
Liu C, Chen X, Yang L, et al. Transcriptional repression of the transforming growth factor β (TGF-β) pseudoreceptor BMP and activin membrane-bound inhibitor (BAMBI) by nuclear factor κB (NF-κB) p50 enhances TGF-β signaling in hepatic stellate cells[J]. J Biol Chem, 2014, 289(10):7082-7091.
|
| 6. |
Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis[J]. J Hepatol, 2014, 60(1):197-209.
|
| 7. |
Zhu Q, Zou L, Jagavelu K, et al. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice[J]. J Hepatol, 2012, 56 (4):893-899.
|
| 8. |
Zhao WX, Wang L, Yang JL, et al. Caffeic acid phenethyl ester attenuates pro-inflammatory and fibrogenic phenotypes of LPS-stimulated hepatic stellate cells through the inhibition of NF-κB signaling[J]. Int J Mol Med, 2014, 33(3):687-694.
|
| 9. |
Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity[J]. Cell, 2010, 140(6):798-804.
|
| 10. |
Chen R, Hou W, Zhang Q, et al. Emerging role of high-mobility group box 1 (HMGB1)in liver diseases[J]. Mol Med, 2013(19):357-366.
|
| 11. |
Li L, Chen L, Hu L, et al. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice[J]. Hepatology, 2011, 54(5):1620-1630.
|
| 12. |
Ge WS, Wu JX, Fan JG, et al. Inhibition of high-mobility group box 1 expression by siRNA in rat hepatic stellate cells[J]. World J Gastroenterol, 2011, 17(36):4090-4098.
|
| 13. |
Zhang Z, Lin C, Peng L. High mobility group box 1 activates Toll like receptor 4 signaling in hepatic stellate cells[J]. Life Sci, 2012, 91(5/6):207-212.
|
| 14. |
Wang FP, Li L, Li J, et al. High mobility group box-1 promotes the proliferation and migration of hepatic stellate cells via TLR4-dependent signal pathways of P13K/Akt and JNK[J]. PLoS One, 2013, 8(5):e64373.
|
| 15. |
Yoshiji H, Kuriyama S, Fukui H. Angiotensin-Ⅰ-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor[J]. Tumour Biol, 2002, 23(6):348-356.
|
| 16. |
Shirai Y, Yoshiji H, Noguchi R, et al. Cross talk between toll-like receptor-4 signaling and angiotensin-Ⅱ in liver fibrosis development in the rat model of non-alcoholic steatohepatitis[J]. J Gastroenterol Hepatol, 2013, 28(4):723-730.
|
| 17. |
Li YS, Ni SY, Meng Y, et al. Angiotensin Ⅱ facilitates fibrogenic effect of TGF-β1 through enhancing the down-regulation of BAMBI caused by LPS:a new pro-fibrotic mechanism of angiotensin Ⅱ[J]. PLoS One, 2013, 8(10):e76289.
|
| 18. |
Shahid SM, Fatima SN, Mahboob T. Angiotensin converting enzyme (ACE) gene expression in experimentally induced liver cirrhosis in rats[J]. Pak J Pharm Sci, 2013, 26(5):853-857.
|
| 19. |
Attia YM, Elalkamy EF, Hammam OA, et al. Telmisartan, an AT1 receptor blocker and a PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infection[J]. Parasit Vectors, 2013(6):199.
|
| 20. |
Roh YS, Seki E. Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis[J]. J Gastroenterol Hepatol, 2013, 28(Suppl 1):38-42.
|
| 21. |
Watanabe A, Hashmi A, Gomes DA, et al. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9[J]. Hepatology, 2007, 46(5):1509-1518.
|
| 22. |
Miura K, Kodama Y, Inokuchi S, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice[J]. Gastroenterology, 2010, 139(1):323-334.
|
| 23. |
Abu-Tair L, Axelrod JH, Doron S, et al. Natural killer cell-dependent anti-fibrotic pathway in liver injury via Toll-like receptor-9[J]. PLoS One, 2013, 8(12):e82571.
|
| 24. |
Wang B, Trippler M, Pei R, et al. Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication[J]. J Hepatol, 2009, 51(6):1037-1045.
|
| 25. |
Paik YH, Lee KS, Lee HJ, et al. Hepatic stellate cells primed with cytokines upregulate inflammation in response to peptidoglycan or lipoteichoic acid[J]. Lab Invest, 2006, 86(7):676-686.
|
